Prostate News and Research

RSS

Developmental epigenetic changes could shape cancer risk later in life

A person's lifetime risk for cancer may begin before they are even born, reports a paradigm-shifting study by Van Andel Institute scientists.

27 Jan 2025

Mount Sinai leads the way with first HYDROS Robotic System procedure in New York City

The Mount Sinai Hospital has performed New York City's first procedure using the HYDROS Robotic System, a cutting-edge technology designed to treat benign prostatic hyperplasia (BPH), or an enlarged prostate.

27 Jan 2025

UH Seidman Cancer Center introduces advanced Varian Ethos 2.0 for cancer treatment

Radiation oncologists at UH Seidman Cancer Center have another powerful treatment option for patients diagnosed with many forms of cancer with the addition of Varian Ethos 2.0, capable of a new form of radiotherapy called adaptive radiotherapy.

24 Jan 2025

Study highlights potential of genomic tests for early stage prostate cancer

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions about how to treat patients with early stage prostate cancer.

24 Jan 2025

Breakthrough study targets tumor cell clusters to prevent metastasis

Certain tumor types do not remain at their point of origin but spread throughout the body and form metastases.

24 Jan 2025

OncoAssure announces clinical validation of prostate cancer test

OncoAssure Ltd, an Irish medical diagnostic company, today announced the publication of new data, in the British Journal of Urology International Compass (BJUI Compass), which demonstrates the clinical validation of OncoAssure Prostate, a novel biopsy test which provides improved estimation of a patient’s risk of prostate cancer recurrence and allows for optimal treatment selection.

21 Jan 2025

Expert consensus provides unified framework for prostate cancer care in China

While prostate cancer is becoming more prevalent among middle-aged and elderly men in China, clinical practice still faces considerable challenges due to the lack of unified guidelines and high-level evidence on several aspects of patient care.

20 Jan 2025

Exploring the use of genomic classifier tests in prostate cancer risk stratification

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for better data on their cost-effectiveness, clinical utility, and their impact on racial and ethnic groups, particularly Black men.

20 Jan 2025

New resource from NCCN offers guidance on hereditary cancer risk

Today, the National Comprehensive Cancer Network (NCCN)-an alliance of leading cancer centers-published a new resource to inform people about the latest recommendations around hereditary and familial cancer risk.

16 Jan 2025

Study finds no increased glioma risk with hormone therapy use

It's not easy being a woman. Just look at the statistics. Women are more likely to have such debilitating conditions as osteoporosis, migraines, Alzheimer disease, depression, multiple sclerosis, and brain tumors. Sex hormones are often blamed. However, a new study suggests no link between hormone therapy (HT) and common brain tumors known as gliomas. Results of the study are published online today in Menopause, the journal of The Menopause Society.

15 Jan 2025

NCCN global meeting focuses on cancer care in the MENA region

The National Comprehensive Cancer Network (NCCN)-a global not-for-profit alliance of leading cancer centers-is taking part in a two-day meeting at the Middle East North Africa (MENA)-NCCN Regional Coordinating Center, beginning today.

11 Jan 2025

Machine learning reveals why cancer trials fall short in real-world patients

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients and enhancing research accuracy.

10 Jan 2025

RNA nanoparticles offer dual action against prostate tumors

Yang Zhang, PhD, and Jinjun Shi, PhD, both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine at Brigham and Women's Hospital, are co-senior authors of a paper published in ACS Nanoscience Au, "Lipid Nanoparticle Delivery of mRNA and siRNA for Concurrent Restoration of Tumor Suppressor and Inhibition of Tumorigenic Driver in Prostate Cancer."

10 Jan 2025

Functional characterization of variants improves cancer risk assessment and treatment

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.

9 Jan 2025

New AI system aims to improve real-world application of clinical trial results

A new study led by Winship Cancer Institute of Emory University and Abramson Cancer Center of University of Pennsylvania researchers demonstrates that a first-of-its-kind platform using artificial intelligence (AI) could help clinicians and patients assess whether and how much an individual patient may benefit from a particular therapy being tested in a clinical trial.

8 Jan 2025